These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 27037533)

  • 1. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
    Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
    BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
    BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
    Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
    Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
    Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
    Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
    Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
    Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
    VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
    Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
    Burgio SL; Conteduca V; Rudnas B; Carrozza F; Campadelli E; Bianchi E; Fabbri P; Montanari M; Carretta E; Menna C; De Giorgi U
    Clin Genitourin Cancer; 2015 Feb; 13(1):39-43. PubMed ID: 24999168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Lewis AR; Costello BA; Quevedo F; Pagliaro LC; Sanhueza C; Weinshilboum RM; Kalari KR; Wang L; Kohli M; Tan W; Giridhar KV
    Prostate; 2023 May; 83(7):649-655. PubMed ID: 36924119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
    Zhao F; Zhao J; Wei X; Shi Y; Xu N; Zhu S; Chen J; Sun G; Dai J; Wang Z; Zhang X; Liang J; Hu X; Liu H; Zhao J; Liu Z; Nie L; Shen P; Chen N; Zeng H
    Prostate; 2024 Jul; 84(10):932-944. PubMed ID: 38629249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
    BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H
    Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
    Fan L; Wang X; Chi C; Wang Y; Cai W; Shao X; Xu F; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Wang R; Zhou L; Dong B; Xue W
    Prostate; 2017 Sep; 77(12):1233-1241. PubMed ID: 28752926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
    Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
    BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.